Mangoceuticals, Inc. Executes Exclusive Distribution Agreement with Propre Energie for Clinically Proven Dermytol®️ Skincare Treatment Targeting Hyperpigmentation

Core Insights - Mangoceuticals, Inc. has entered into an exclusive Master Distribution Agreement with Propre Energie, Inc. to market and distribute Dermytol®, a clinically proven skincare treatment aimed at improving skin tone and reducing hyperpigmentation [1][5] Company Overview - Mangoceuticals, Inc. focuses on developing and selling men's wellness products through a secure telemedicine platform, with a growing portfolio that includes various health and wellness solutions [7][8] - Propre Energie, Inc. specializes in plant-based, non-retinol skincare solutions under the Dermytol® brand, emphasizing research and innovation in developing safe and effective products [6] Product Details - Dermytol® is an advanced, plant-based formula designed to address pigmentation issues such as dark spots and uneven skin tone, utilizing a proprietary blend of clinically validated ingredients [2][3] - The formulation includes canola phenolic acid, Camellia sinensis tea extract, evening primrose, and aloe vera, providing a safer alternative to traditional skin treatments like hydroquinone [2] Market Insights - The global skincare market is projected to reach approximately $218 billion by 2029, with a compound annual growth rate (CAGR) of 3.61$789.75 million in 2023 to $1.62 billion by 2033, reflecting a robust CAGR of 7.5% over the next decade, driven by consumer demand for natural and effective skincare solutions [4] Strategic Partnership - The partnership allows Mangoceuticals to leverage its marketing and distribution infrastructure to accelerate Dermytol®'s penetration in North and South American markets, with the product available in both patch and cream formulations [5]